Caricamento...
ACTR-67. PLASMA AND TUMOR PHARMACOKINETICS OF RIBOCICLIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
BACKGROUND: CDK4/6-dependent cell-cycle regulation is disrupted in 78% of glioblastoma (GBM) patients and novel CDK4/6 inhibitors have shown anti-tumor activity in animal models. To explore the utility of ribociclib, a selective CDK4/6-inhibitor, in treating recurrent GBM patients, we conducted a ph...
Salvato in:
| Pubblicato in: | Neuro Oncol |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692032/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.054 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|